Professor Martin Landray
- Accurately estimating the burden of vascular disease using electronic health records
- Analysing big data from electronic health records to understand the determinants of cardiovascular disease
- Deep phenotyping of vascular events in large-scale epidemiological studies using electronic health records
- Big Data Institute (BDI)
MB ChB, PhD, FRCP, FHEA, FASN, FBPhS, FESC
Professor of Medicine and Epidemiology
- Research Director, Health Data Research UK
- Acting Director, Big Data Institute
- Lead, Big Data & Computing Innovation, MRC Population Health Research Unit
- Lead, Clinical Informatics & Big Data, NIHR Oxford Biomedical Research Centre
- Lead, Health Informatics Hub, UK Biobank
- Honorary Consultant Physician, Oxford University Hospitals NHS Foundation Trust
Prof Landray’s work seeks to further understanding of the determinants of common diseases through the design, conduct and analysis of efficient, large-scale clinical trials and prospective cohort studies (including UK Biobank). He has led a series of major clinical trials assessing treatments for cardiovascular and kidney disease. These have enrolled over 65,000 individuals, producing results that have changed regulatory drug approvals, influenced clinical guidelines and changed prescribing practice to the benefit of patients.
He is heavily involved in efforts to streamline clinical trials, working with regulatory agencies to facilitate efficient and cost-effective trials. He is a member of the Steering Committee of the FDA Clinical Trial Transformation Initiative, leading the Monitoring, Quality by Design, and Mobile Clinical Trials projects. He is a member of the NHS Digital Research Advisory Group and the NICE Data & Analytics External Reference Group, and leads the 21st Century Clinical Trials programme for Health Data Research UK.
Prof Landray completed medical training at University of Birmingham (UK) and specialist training in Clinical Pharmacology & Therapeutics, and General Internal Medicine at University of Birmingham. He continues to practise clinical medicine as an Honorary Consultant Physician in the Cardiology, Cardiac and Thoracic Surgery Directorate at Oxford University Hospitals NHS Trust. He is a Fellow of the Royal College of Physicians of London, the Higher Education Academy, the British Pharmacological Society, and the European Society of Cardiology.
The Magic of Randomization versus the Myth of Real-World Evidence.
Collins R. et al, (2020), N engl j med, 382, 674 - 678
Accelerometer-measured physical activity and functional behaviours among people on dialysis
Nawab K. et al, (2020), Clinical kidney journal
Investigating modifications to participant information materials to improve recruitment into a large randomized trial.
HPS2-THRIVE Collaborative Group None. et al, (2019), Trials, 20
Serious Adverse Effects of Extended-Release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.
Haynes R. et al, (2019), Clin ther
Physical activity, sleep and cardiovascular health data for 50,000 individuals from the MyHeart Counts Study.
Hershman SG. et al, (2019), Sci data, 6
IN the News
Lectures, webcasts and interviews
Big Trials, Big Data, Big Potential: population health research in the 21st century
Inaugural Lecture, University of Oxford, November 2015
New Technologies for Healthcare Research
Oxford Martin School, University of Oxford, January 2016
Big Data for Efficient Clinical Trials
National Academy of Medicine, Washington DC, October 2015
Big Data in Biomedicine
Interview, Stanford Medicine, May 2015
Quality by Design for Clinical Trials
Clinical Trial Transformation Initiative, Bethesda, April 2015
Big Data in Biomedicine
Interview, Stanford Medicine, May 2014
Big Data and Drug Discovery
University of Oxford Alumni, October 2013